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MinireviewA RIP Tide in Neuronal
Signal Transduction
regulatory element binding protein (SREBP) is a resident
protein of the endoplasmic reticulum that contains two
transmembrane domains in a hairpin configuration (Hua
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et al., 1995). Upon cholesterol depletion, SREBP is trans-Division of Neuroscience
located to the Golgi complex by SREBP-activating pro-The Children’s Hospital
tein (SCAP), which functions as a cholesterol sensor inEnders 260
the membrane of the endoplasmic reticulum (Wang et300 Longwood Avenue
al., 1994). After translocation to the Golgi, SREBP-1 isBoston, Massachusetts 02115
cleaved first in the lumen and then in the transmembrane
domain, releasing the N-terminal cytoplasmic fragment.
The released fragment is translocated to the nucleusThe generation of nuclear signaling proteins by regu-
where it activates expression of genes involved in lipidlated intramembrane proteolysis (RIP) is a new para-
biosynthesis through basic helix-loop-helix motifsdigm of signal transduction. Mammalian proteins that
(Brown and Goldstein, 1997). Thus, in the case ofare processed by RIP include SREBP-1, Notch-1, amy-
SREBP-1, the RIP-inducing signal functions by translo-loid precursor protein (APP), and ErbB-4. Intramem-
cating the target protein to another cellular compart-branous -secretase cleavage of APP plays a central
ment where proteolysis occurs (Figure 1).role in Alzheimer’s disease by generating the amyloid
The Role of RIP in Notch Signaling protein. An intriguing possibility is that the cognate
and APP MetabolismC-terminal fragment generated by -secretase cleav-
The discovery that both Notch and amyloid precursorage could also play a role through the regulation of
protein (APP) are processed by RIP generated consider-nuclear signaling events. Thus, RIP may contribute to
able excitement because of potential implications forboth brain development and degeneration and may
understanding basic mechanisms of brain developmentprovide unexpected diversity to the signaling reper-
and degeneration. RIP was implicated in Notch-1 signal-toire of a cell.
ing by the observations of Kopan and colleagues
(Schroeter et al., 1998) who showed that upon ligandOne of the major advances in neurobiology has been
binding, intramembrane cleavage of Notch-1 generatedthe elucidation of signal transduction mechanisms that
a transcriptionally active fragment, the Notch intracellu-underlie the essential functions of the nervous system.
lar domain (NICD). Knockin mice with a mutation thatThe classic paradigm has involved the binding of a li-
inhibits Notch-1 intramembrane cleavage exhibit manygand to a receptor, which then transduces a signal via
of the features of mice deficient for CSL, a transcriptionion fluxes or kinase signaling cascades. This simple
factor downstream of Notch, providing strong supportconstruct has explained an enormous variety of biologi-
for the biological significance of RIP in Notch signalingcal phenomena in the nervous system, from synaptic
(Huppert et al., 2000).plasticity to apoptosis (Yuan and Yankner, 2000). How-
In contrast to the role of RIP in Notch signaling andever, recent reports from several groups suggest that a
brain development, RIP may play a central role in thenovel signaling paradigm, called “regulated intramem-
neurodegenerative process in Alzheimer’s diseasebrane proteolysis” (RIP), may provide new and unex-
through generation of the amyloid  protein (A). A
pected diversity to the signaling repertoire of a cell.
is generated from APP through the combination of an
RIP occurs when a transmembrane protein is cleaved
N-terminal cleavage (-secretase), followed by an intra-
within the membrane, releasing a cytoplasmic fragment membrane (-secretase) cleavage. Although aggre-
that can act directly in the nucleus to activate gene gated A is the primary constituent of senile plaques in
expression. RIP requires two cleavage events. The first Alzheimer’s disease, the generation of A at low levels
occurs outside the membrane, often in response to li- occurs by RIP in most cell types.
gand binding, and results in a conformational change The mechanism of RIP is strikingly similar for Notch
that triggers a second intramembrane cleavage event, and APP. Notch undergoes an initial cleavage in the
which releases an active cytoplasmic fragment. The cy- Golgi by furin convertase to create a heterodimeric
toplasmic fragment then translocates to the nucleus and Notch receptor at the cell surface. Ligand binding results
activates gene expression. Thus, RIP results in quick in a second extracellular cleavage that triggers intra-
and direct activation of target genes, bypassing adaptor membrane proteolysis and the release of the NICD sig-
proteins and kinase cascades. RIP is less modifiable naling fragment. Similarly, APP is initially cleaved in ei-
but possibly more definitive in its end result than classic ther of two different N-terminal sites outside the
kinase signaling cascades. As such, it may be utilized membrane (- or -secretase cleavage sites), which
to transduce binary signals that do not require the inte- then triggers intramembrane or -secretase cleavage
gration of multiple cellular inputs. (Figure 1). Moreover, the same proteases may mediate
SREBP and the Discovery of RIP these cleavages in Notch-1 and APP.
The discovery of RIP arose from studies of the transcrip- Mutations in the presenilin genes are a major cause
tional regulation of cholesterol metabolism. The sterol of early onset familial Alzheimer’s disease (Sherrington
et al., 1995). Several lines of evidence suggest that the
presenilins are part of a large macromolecular complex1Correspondence: bruce.yankner@tch.harvard.edu
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Figure 1. Signaling by Regulated Intramembrane Proteolysis
Several proteins known to signal by RIP are illustrated. Upon cholesterol depletion, SREBP is transported to the Golgi, where it undergoes
intraluminal cleavage (site 1) followed by transmembrane cleavage (site 2). Consequently, an N-terminal fragment is released that translocates
to the nucleus and activates transcription of lipid biosynthetic genes. Binding of the ligand Delta to its receptor Notch triggers intramembrane
proteolytic cleavage by -secretase. This results in the release of the Notch intracellular domain (NICD), which then translocates to the nucleus
where it associates with the CSL family of DNA binding proteins and transactivates gene expression. Constitutive -secretase cleavage of
APP leads to the generation of the CTF fragment. In overexpression systems, this fragment associates with the adaptor protein Fe65 in the
nucleus to form an active transcriptional complex with the histone acetyltransferase Tip60. An additional unidentified factor (?) may be a
component of the complex. Activation of the receptor tyrosine kinase (ErbB-4) by its ligand neuregulin can trigger the proteolytic release of
the ErbB-4 C-terminal fragment (ErbB-4/CTF). The cleaved fragment translocates to the nucleus where it may affect transcription.
that mediates intramembrane cleavage of both Notch-1 extracellular and intramembrane cleavage events would
be unexpected if the sole purpose were protein turnover.and APP. First, cells completely deficient in presenilins
exhibit absence of RIP for Notch and APP, as manifested To explore a biological function for the -secretase
cleavage of APP, Cao and Sudhof (2001) determinedby the inability to detect the generation of A and the
Notch-1 intracellular fragment (Zhang et al., 2000; Herre- whether the released C-terminal fragment of APP could
have transcritional activity by creating fusion proteinsman et al., 2000). Second, highly specific transition state
analogs of -secretase bind specifically to presenilins of APP or the released APP C-terminal fragment with
the DNA binding domains of Gal4 and LexA. These con-and inhibit intramembrane cleavage of both Notch and
APP (Li et al., 2000; Esler et al., 2000). Although it has structs did not stimulate transcription themselves. How-
ever, coexpression with Fe65, an adaptor protein thatbeen suggested that presenilins are the RIP proteases,
it remains to be definitively determined whether preseni- binds to the APP C-terminal domain, resulted in a
2000-fold increase in transcription from an exogenouslins are proteases or regulatory components of a multi-
protein complex containing another protease. reporter. They further showed that the APP C-terminal
domain and Fe65 form a transcriptionally active complexAlthough RIP plays a central role in Notch signaling,
the role of RIP in the biological function of APP is less with Tip60, a histone acetyltransferase involved in the
regulation of transcription, chromatin remodeling, andclear. Intramembrane cleavage of APP generates both
A and a C-terminal cytoplasmic fragment. However, in DNA repair. Moreover, in overexpression systems, sev-
eral groups have shown that the APP C-terminal frag-contrast to the signaling fragments generated by RIP of
SREBP-1 and Notch, which are large protein fragments ment can enter the nucleus and is stabilized by Fe65 in
both primary neurons and nonneuronal cells (Cupers etthat contain classic transcriptional activation motifs, the
C-terminal fragment generated by RIP of APP is quite al., 2001; Kimberly et al., 2001). These observations raise
the exciting possibility that -secretase cleavage of APPsmall (57–59 residues) and does not exhibit any clear
nuclear localization or signaling motifs. Furthermore, the may be involved in the regulation of nuclear events that
could potentially contribute to the pathogenesis of Alz-regulation of Notch and APP cleavages are different.
Notch undergoes intramembrane cleavage in response heimer’s disease.
RIP is likely to contribute to Alzheimer’s diseaseto ligand binding and activation, whereas APP appears
to undergo intramembrane cleavage constitutively. Nev- through its well-established role in the generation of
A. The intramembrane -secretase cleavage of APP isertheless, the sequential processing of APP by discrete
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fragments mediate nuclear signaling and that this path-
way can contribute to neurodegeneration when APP or
presenilin mutations are introduced.
Can Classic Receptor Tyrosine Kinases
Signal by RIP?
RIP appears to serve as a primary signaling mechanism
for SREBP-1 and Notch. However, two recent reports
suggest that a classic receptor tyrosine kinase, ErbB-4,
may also signal through RIP (Ni et al., 2001; Lee et al.,
2002). Like the other RIP substrates, ErbB-4 undergoes
two cleavage events. The initial cleavage in the extracel-
lular domain is mediated by the metalloprotease TACE
(Rio et al., 2000), which has also been implicated in
the extracellular -secretase cleavage of APP. This is
followed by intramembrane cleavage mediated by
-secretase/presenilin, which results in translocation of
the C-terminal domain to the nucleus. Moreover, Ni and
Figure 2. Does RIP-Mediated Nuclear Signaling Contribute to Alz- colleagues (2001) showed that a fusion protein of the
heimer’s Disease? ErbB-4 C-terminal domain to the DNA binding domain
The predominant cytoplasmic fragment generated by -secretase of Gal4 has weak transcriptional activity. Furthermore,
cleavage of APP is predicted to be CTF59. It has been hypothesized they provided evidence that -secretase cleavage of
that this results in nuclear signaling and the activation of genes
ErbB-4 plays a physiological role by showing that ErbB-required for APP-mediated cellular processes. A consequence of
4-induced growth effects can be blocked by inhibitingpresenilin mutations that cause familial Alzheimer’s disease (AD)
-secretase cleavage.may be an increase in the production of an alternative C-terminal
fragment, CTF57, which accompanies the production of a 42 amino As for APP, it remains to be determined whether en-
acid amyloid  protein. CTF57 could potentially contribute to AD dogenous ErbB-4 mediates nuclear signaling. It is still
pathology through pro-apoptotic signaling or by interfering with possible that -secretase cleavage might facilitate
normal CTF59 signaling mechanisms. Alternatively, CTF57 may
ErbB-4 signaling through activation of protein kinase C,not be efficiently processed to a smaller, more active fragment,
MAP kinase, or PI3 kinase, known targets of ErbB-4 sig-CTF50, which some studies suggest is the ultimate cytoplasmic
naling in the cytoplasm. Nevertheless, these findingsproduct of APP transmembrane processing.
raise the intriguing possibility that the same receptor may
signal through both classic kinase cascades and RIP.
Future Directionsheterogeneous, resulting in the generation of two major
The role of RIP in neuronal signal transduction is excitingforms of A that are 40 and 42 amino acids in length.
and potentially important from the standpoint of bothIt is believed that the 42 amino acid form is pathogenic
physiology and disease. It is likely that the number ofbecause it is highly aggregable and is the major compo-
signaling proteins processed by RIP will increase innent of senile plaques, and may be more neurotoxic than
number, but a key question is whether RIP will turn outthe 40 amino acid form (Yankner, 1996). The genetics of
to be a general signaling pathway for many receptorfamilial Alzheimer’s disease strongly support the cen-
tyrosine kinases or a highly specialized mechanism. RIPtrality of this mechanism in the pathogenesis of Alzhei-
has been difficult to detect because the releasedmer’s disease. Autosomal dominant mutations in APP
C-terminal fragment is often unstable, a technical limita-or the presenilin genes have been shown to increase
tion which delayed the elucidation of this pathway inthe relative production of the pathogenic 42 amino acid
Notch signaling.peptide (Selkoe, 1999). An intriguing question is whether
Although the nuclear signaling pathways identified forthe C-terminal fragment that is released along with A42
APP and ErbB-4 are intriguing, it remains to be estab-contributes to the neurodegenerative process. Ac-
lished whether the endogenous proteins can translocatecording to this model, the benign A40-generating intra-
to the nucleus and affect signaling. Moreover, the targetmembrane cleavage produces a 57 amino acid C-ter-
genes that are activated by these putative signalingminal fragment that would mediate physiological nuclear
events are unknown. Another important issue is the reg-signaling. The A42-generating cleavage, however, would
ulation of RIP. Intramembrane cleavage of Notch andrelease a longer 59 amino acid C-terminal that may im-
ErbB-4 RIP is triggered by ligand binding, but intramem-pede signaling from the physiological fragment or could
brane cleavage of APP appears to occur constitutively.signal aberrantly (Figure 2). An alternative model is
An intriguing possibility is that an unknown ligand maybased on the observation that a shorter 50 amino acid
also activate intramembrane cleavage of APP, resultingC-terminal fragment is generated from a second trans-
in the generation of A and the activation of nuclearmembrane cleavage site in APP that is located in a
signaling. The importance of these questions for Alzhei-position similar to the Notch-1 -secretase site (Sastre
mer’s disease and signal transduction biology will en-et al., 2001; Gu et al., 2001; Yu et al., 2001). Thus, CTF
gage a diverse group of investigators in the years to57 and CTF 59 may be penultimate fragments that are
come.processed further to a 50 amino acid fragment that may
mediate signaling. The potentially deleterious CTF 57 Selected Reading
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